Therefore, in accordance with our earlier antibody findings, we suggest that future B cell-based influenza vaccines promoting cross-reactive B cell responses encompassing both activated-memory IgA+ and IgG+ subclasses may provide further protection at the site of infection. The gene discussed is CD79A; the disease is influenza.